SynthesisJournal of thrombosis and thrombolysis2026
Impact of antithrombin III deficiency on clinical outcomes in trauma patients: a systematic review and meta-analysis.
Synthesis in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntithrombin III (ATIII) is a key regulator of coagulation, playing a vital role in maintaining hemostatic balance. Reduced ATIII levels have been observed in trauma patients, potentially contributing to an increased risk of mortality, thromboembolic events, and coagulopathy. While ATIII deficiency has been associated with worse clinical outcomes in critically ill patients, less is known about its impact on trauma patient populations. PURPOSE: This meta-analysis aims to evaluate the association between ATIII deficiency and clinical outcomes, including mortality, thromboembolism, disseminated intravascular coagulation (DIC), and shock in trauma patients.
methodsPubMed, Embase, and the Cochrane Library databases were searched for randomized trials and observational studies that compared trauma patients with ATIII deficiency with those with normal ATIII levels and reported outcomes related to mortality, thromboembolic events, DIC, and shock. Heterogeneity was assessed using the I² statistic. A random-effects model was applied to all outcomes to account for potential variations across studies.
resultsWe included nine observational studies with a total of 1,629 trauma patients, all of which contributed data to at least one analyzed outcome. Compared with trauma patients with normal ATIII levels, those with ATIII deficiency had an association with a higher risk of mortality (pooled OR 3.61; 95% CI 2.36–5.50; p < 0.01), thromboembolic events (pooled OR 2.14; 95% CI 1.21–3.80; p = 0.009), and shock (pooled OR 4.65; 95% CI 3.16–6.83; p < 0.01). However, no difference was found for DIC between groups (pooled OR 6.63; 95% CI 0.89–49.44; p = 0.06).
conclusionThese findings suggest that ATIII deficiency is associated with worse clinical outcomes in trauma patient populations. Further research is needed to determine whether targeted ATIII management strategies could improve outcomes in trauma patients.
Indexed as
Identifiers
40813531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.